Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
about
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching studyNew perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.Hepatocellular carcinoma metastasis to the gingival soft tissues: A case report and review of the literature.Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis.Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinomaEndovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus.Current management of hepatocellular carcinoma: an Eastern perspective.Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus.The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature reviewCombination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study.Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysisWould you like to leave Beijing, Shanghai, or Shenzhen? An empirical analysis of migration effect in China
P2860
Q33914180-A5CE0ECF-3975-4A56-AB6B-01E456822DA9Q34265415-B6031483-0EB3-4D6E-B2B5-6AD86E7252D9Q35091836-F702EB14-FF0D-4B40-A90C-9BEACCE003B1Q35824064-013FABBC-6712-4F0F-8158-1FA7471B03C4Q35944462-557E47C3-CD59-4F64-AEDA-806ADE7395DDQ36772220-61DDB7F6-5689-4D55-BE73-A5F0E47D3540Q37687559-C72F03D2-34BE-46C9-A2ED-6FA23090728CQ37696388-47D82963-C4D5-4F04-957C-1F43B7DF114BQ37707056-016DBFC5-A0FC-4E3E-B0F5-D6ACB217A998Q38410816-2ACD8928-34A3-43F9-BEBF-6759FAE41B3EQ40571907-06D7AEED-6521-4BB6-8053-4869E4726C00Q41172447-A6DA333B-6126-49CB-9FF2-5AE75CC03EFFQ41362230-532D204F-2028-41BF-A993-C837E01B1893Q41915464-1DDF5C54-69F6-461C-BA2F-A57D9DE160A3Q47094775-55264369-399F-4CE8-BC5E-F272EAB5CAB1Q47169633-F465C8A7-B65E-4673-B48B-1E14CB3E3882Q48722303-EDCA3055-2050-48E1-81D1-4C35E29D5E2CQ49627939-24A38045-ADB7-48F0-AB68-A4B3AEEDE03FQ52604161-CFFE97EE-EA87-4420-A01D-1C4E76D2D4FAQ58765170-3F5A624E-59F1-496A-9E99-7CA2A4C79A64Q58775128-6BDB9672-9A9B-449F-8567-3A5EACD12ED7
P2860
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sorafenib combined with transa ...... opensity score matching study.
@ast
Sorafenib combined with transa ...... opensity score matching study.
@en
type
label
Sorafenib combined with transa ...... opensity score matching study.
@ast
Sorafenib combined with transa ...... opensity score matching study.
@en
prefLabel
Sorafenib combined with transa ...... opensity score matching study.
@ast
Sorafenib combined with transa ...... opensity score matching study.
@en
P2093
P2860
P1433
P1476
Sorafenib combined with transa ...... opensity score matching study.
@en
P2093
Haibin Shi
Xiaoran Long
Yancu Hertzanu
Zhengqiang Yang
Zhenhua Duan
P2860
P304
P356
10.1371/JOURNAL.PONE.0096620
P407
P577
2014-05-09T00:00:00Z